Migraine individuals had significantly higher annual cost over non-migraineurs from 2004 to 2013. Trends in adjusted incremental annual cost in migraineurs were insignificant from 2004 to 2013. Aggregated adjusted incremental annual cost in migraineurs was estimated to be $9.20 billion/year. Study findings suggest a need for novel interventions to reduce excess expenditures with migraine.